980 related articles for article (PubMed ID: 16429394)
21. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Lee AH; Ellis IO
Histopathology; 2007 Mar; 50(4):434-8. PubMed ID: 17448018
[TBL] [Abstract][Full Text] [Related]
22. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
Arnes JB; Bégin LR; Stefansson I; Brunet JS; Nielsen TO; Foulkes WD; Akslen LA
J Clin Pathol; 2009 Feb; 62(2):139-46. PubMed ID: 18682421
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer.
Yamamoto Y; Ibusuki M; Okumura Y; Kawasoe T; Kai K; Iyama K; Iwase H
Breast Cancer Res Treat; 2008 Aug; 110(3):465-75. PubMed ID: 17805961
[TBL] [Abstract][Full Text] [Related]
24. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status.
Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
Cancer; 2009 Nov; 115(21):4917-23. PubMed ID: 19691094
[TBL] [Abstract][Full Text] [Related]
25. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
[TBL] [Abstract][Full Text] [Related]
26. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
27. Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status.
Shin BK; Lee Y; Lee JB; Kim HK; Lee JB; Cho SJ; Kim A
Oncol Rep; 2008 Mar; 19(3):617-25. PubMed ID: 18288392
[TBL] [Abstract][Full Text] [Related]
28. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
[TBL] [Abstract][Full Text] [Related]
29. The phenotypic spectrum of basal-like breast cancers: a critical appraisal.
Fadare O; Tavassoli FA
Adv Anat Pathol; 2007 Sep; 14(5):358-73. PubMed ID: 17717437
[TBL] [Abstract][Full Text] [Related]
30. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
31. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
[TBL] [Abstract][Full Text] [Related]
32. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.
Ishihara A; Tsuda H; Kitagawa K; Yoneda M; Shiraishi T
Breast Cancer; 2009; 16(3):179-85. PubMed ID: 19466513
[TBL] [Abstract][Full Text] [Related]
33. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.
Viale G; Rotmensz N; Maisonneuve P; Bottiglieri L; Montagna E; Luini A; Veronesi P; Intra M; Torrisi R; Cardillo A; Campagnoli E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2009 Jul; 116(2):317-28. PubMed ID: 18839307
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.
Rodríguez-Pinilla SM; Sarrió D; Honrado E; Hardisson D; Calero F; Benitez J; Palacios J
Clin Cancer Res; 2006 Mar; 12(5):1533-9. PubMed ID: 16533778
[TBL] [Abstract][Full Text] [Related]
35. Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis.
Rakha EA; Pinder SE; Paish EC; Robertson JF; Ellis IO
J Pathol; 2004 Jul; 203(3):754-61. PubMed ID: 15221934
[TBL] [Abstract][Full Text] [Related]
36. Expression of luminal and basal cytokeratins in human breast carcinoma.
Abd El-Rehim DM; Pinder SE; Paish CE; Bell J; Blamey RW; Robertson JF; Nicholson RI; Ellis IO
J Pathol; 2004 Jun; 203(2):661-71. PubMed ID: 15141381
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma.
Yang Q; Yoshimura G; Suzuma T; Tamaki T; Umemura T; Nakamura M; Nakamura Y; Wang X; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2001 Dec; 7(12):3869-73. PubMed ID: 11751477
[TBL] [Abstract][Full Text] [Related]
38. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast.
Grenier J; Soria JC; Mathieu MC; Andre F; Abdelmoula S; Velasco V; Morat L; Besse B; Dunant A; Spielmann M; Delaloge S
Anticancer Res; 2007; 27(1B):547-55. PubMed ID: 17348440
[TBL] [Abstract][Full Text] [Related]
39. BRCA1 expression in invasive breast carcinomas and clinicopathological correlations.
Comănescu M; Popescu CF
Rom J Morphol Embryol; 2009; 50(3):419-24. PubMed ID: 19690768
[TBL] [Abstract][Full Text] [Related]
40. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer.
Lipponen P; Saarelainen E; Ji H; Aaltomaa S; Syrjänen K
J Pathol; 1994 Oct; 174(2):101-9. PubMed ID: 7965405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]